Filtered By:
Specialty: Drugs & Pharmacology
Condition: Obesity
Infectious Disease: Epidemics

This page shows you your search results in order of date.

Order by Relevance | Date

Total 4 results found since Jan 2013.

A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes.
Abstract Cardiovascular diseases (CVDs) are the leading cause of premature death and disability in humans and their incidence is on the rise globally. Given their substantial contribution towards the escalating costs of health care, they also generate a high socio-economic burden in the general population. The underlying pathogenesis and progression associated with nearly all CVDs is predominantly of atherosclerotic origin that leads to the development of coronary artery disease, cerebrovascular disease, venous thromboembolism and, peripheral vascular disease, subsequently causing myocardial infarction, cardiac ar...
Source: Current Pharmaceutical Design - September 24, 2019 Category: Drugs & Pharmacology Authors: Flora GD, Nayak MK Tags: Curr Pharm Des Source Type: research

Translational Significance of Heme Oxygenase in Obesity and Metabolic Syndrome
Publication date: Available online 26 October 2015 Source:Trends in Pharmacological Sciences Author(s): Nader G. Abraham, Joshua M. Junge, George S. Drummond The global epidemic of obesity continues unabated with sequelae of diabetes and metabolic syndrome. This review reflects the dramatic increase in research on the role of increased expression of heme oxygenase (HO)-1/HO-2, biliverdin reductase, and HO activity on vascular disease. The HO system engages with other systems to mitigate the deleterious effects of oxidative stress in obesity and cardiovascular disease (CVD). Recent reports indicate that HO-1/HO-2 prote...
Source: Trends in Pharmacological Sciences - October 27, 2015 Category: Drugs & Pharmacology Source Type: research

Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease.
Abstract There is a global epidemic of obesity, metabolic syndrome, and diabetes mellitus. Insulin resistance (IR) is etiologic for both metabolic syndrome and diabetes mellitus. IR induces a broad range of toxic systemic effects, including dyslipidemia, hypertension, hyperglycemia, increased production of advanced glycosylation end products, increased inflammatory tone, as well as a prothrombotic and pro-oxidative state. Patients with IR are highly vulnerable to the development of accelerated atherosclerosis as well its clinical sequelae, including coronary artery disease and myocardial infarction, carotid artery...
Source: Current Vascular Pharmacology - April 25, 2013 Category: Drugs & Pharmacology Authors: Toth PP Tags: Curr Vasc Pharmacol Source Type: research

Drug treatments to restore vascular function and diabesity.
Abstract Over the last decades, an escalating rate of type 2 diabetes has paralleled an epidemic rise in the prevalence of obesity. Both diabetes and obesity confer an increased risk of cardiovascular comorbidities, including hypertension, coronary artery disease and stroke. Vascular dysfunction, represented by impaired endothelial release of vasodilator substances or defective smooth muscle vasodilator reactivity, is the early stage of the process leading to atherosclerosis and a common finding in patients with diabesity. It is understandable, therefore, that effective treatments for diabesity should restore vasc...
Source: Annales Pharmaceutiques Francaises - January 1, 2013 Category: Drugs & Pharmacology Authors: Cardillo C Tags: Ann Pharm Fr Source Type: research